Medicare's annual open enrollment period began Oct. 15, allowing seniors to choose new plans. New rules this year are supposed to crack down on misleading marketing but buyers should still beware.

About 12 million Americans are known as "dual eligibles" because they need both Medicare and Medicaid. A bipartisan bill offers hope to cut through the tangle of red tape that often ensnares them.

Medicare soon will start something it hasn't done in its 58-year history: Negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

The end-of-life benefit costs billions a year. A new approach aims to eliminate waste and weed out bad actors, while making the care more inviting to those who most need it.

Drugmakers will be required to pay Medicare back for price increases that outpace inflation. The industry is expected to put up a fight over implementation.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

The Inflation Reduction Act gives Medicare historic new powers to limit prescription drug prices. But the pharmaceutical industry is already lobbying to dull their impact.

Over 9 million Americans have lost both their job and health coverage. To help them, COBRA is an option, but it could cost buyers more than if subsidies were increased for Affordable Care Act plans.

Matching the sickest patients with social workers and medical support doesn't reduce costly hospital readmissions, a study finds. Still, some believe greater social investment could make a difference.